Taken together, our results indicated that PD-L1 expression on monocytes could serve as an optimal therapeutic indicator for anti-PD-L1 immune therapy for NKTCL patients, which needed further validation in prospective clinical cohorts. The gene discussed is CD274; the disease is extranodal nasal NK/T cell lymphoma.